Your browser doesn't support javascript.
loading
Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey.
Ferrandina, Gabriella; Amadio, Giulia; Paris, Ida; Distefano, Mariagrazia; Palluzzi, Eleonora; de Vincenzo, Rosa; Ricci, Caterina; Scambia, Giovanni.
Afiliação
  • Ferrandina G; *Department of Health Sciences and Medicine, University of Molise, Campobasso; †Gynecologic Oncology Unit, Department Obstetrics/Gynecology, Fondazione "Policlinico Universitario A. Gemelli", Rome; and ‡Catholic University of Rome, Italy.
Int J Gynecol Cancer ; 27(6): 1141-1148, 2017 07.
Article em En | MEDLINE | ID: mdl-28574933
ABSTRACT

BACKGROUND:

Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients.

METHODS:

We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions.

RESULTS:

Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%.

CONCLUSIONS:

This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Padrões de Prática Médica / Protocolos de Quimioterapia Combinada Antineoplásica / Oncologistas / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Limite: Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Padrões de Prática Médica / Protocolos de Quimioterapia Combinada Antineoplásica / Oncologistas / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Qualitative_research Limite: Female / Humans País como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article